School of Clinical Medicine
Centre of Cancer Medicine


About Us

 

The Centre of Cancer Medicine (CancerMed) was established in October 2022 under the umbrella of the School of Clinical Medicine (SClinMed) to serve as a holistic platform to facilitate the academic development of oncology, and to foster collaboration amongst the cognate disciplines/(sub)specialties both within SClinMed and with other Schools, Departments, Institutes, Hospitals and Colleges in cancer prevention, diagnosis, treatment, research and education.


Objectives of the Centre of Cancer Medicine are:

  • to promote academic development of oncology;
  • to consolidate and enhance the critical mass of oncology specialists, and to attract and nurture the next generation clinician and scientists in cancer management and research;
  • to foster integrated approach to oncology teaching for medical students; and
  • to achieve synergism, promote interdisciplinary collaborations and enhance coordination of clinical services, amongst a wide array of cognate units within HKU, as well as the Hong Kong’s first academic cancer centre at Grantham Hospital.

The Centre of Cancer Medicine comprises the Department of Clinical Oncology and networks closely with the HKUMed’s flagship programmes on cancer including the Centre for Clinical Innovation and Discovery (CCID) and Institute of Cancer Care (ICC).

Department of Clinical Oncology
Jockey Club Centre for Clinical Innovation and Discovery (CCID)
Jockey Club Institute of Cancer Care (ICC)

Director
Professor Rina Hui
Clinical Professor and Director, Centre of Cancer Medicine

Professor Rina Hui assumes Directorship of the Centre of Cancer Medicine in January 2023. She is a well-established medical oncologist specialising in breast and lung cancers as well as a passionate educator.

After completing her medical degree at The University of Sydney and specialist training at The Royal North Shore Hospital, Rina undertook translational research in cyclin D1-CDK4/6-p16INK4a-pRb pathway in breast cancer at the Garvan Institute of Medical Research and was awarded a PhD degree. Before joining HKU, Rina was a Clinical Professor at the University of Sydney and a Senior Medical Oncologist at the Crown Princess Mary Cancer Centre, Westmead Hospital, Sydney, Australia. She served as Co-Chair of the Oncology Block teaching at the University of Sydney and served in the written examination committee for the Royal Australasian College of Physician. She was also the Head of Clinical Trials at the Westmead Breast Cancer Institute, a member of the clinical advisory board and research advisory committee of the Westmead Breast Cancer Institute, a member of the Medical Oncology Group of Australia Expert Group for lung cancer, a member of the Basic Sciences of Oncology Course Subject Matter Expert Group, a member of the Breast Cancer Trials and the Thoracic Oncology Group of Australasia. Rina was a member of the scientific program committee for European Society of Medical Oncology Congress in 2021 and 2022. Rina has been principal investigator on many clinical trials, including phase I as well as many landmark practice-changing phase III clinical studies of immunotherapy and targeted therapies in breast and lung cancers over the years resulting in publications in highly ranked journals.

10 MOST SIGNIFICANT PUBLICATIONS:

  1. Pembrolizumab for the Treatment of Non-small Cell Lung Cancer (Times cited: ~5,560)

    Edward Garon, Naiyer Rizvi, Rina Hui, Natasha Leighl, Ani Balmanoukian, Joseph Elder, Amita Patnaik, Charu Aggarwal, Matthew Gubens, Leora Horn, Enric Carcereny, Myung-Ju Ahn, Enriqueta Felip, Jong-Seok Lee, Matthew Hellmann, Omid Hamid, Jonathan Goldman, Jean-Charles Soria, Marisa Dolled-Filhart, Ruth Rutledge, Jin Zhang, Jared Lunceford, Reshma Rangwala, Gregory Lubiniecki, Charlotte Roach, Kenneth Emancipator, Leena Gandhi.

    New England Journal of Medicine, 372 (21):2018-2028, 2015.
  2. Pembrolizumab versus Chemotherapy for PD-L1-positive Non-small Cell Lung Cancer (Times cited: ~7,863)

    Martin Reck, Delvys Rodriguez-Abreu, Andrew G Robinson, Rina Hui, Tibor Gsoszi, Andrea Fulip, Maya Gottfried, Nir Peled, Ali Tafreshi, Sinead Cuffe, Mary O’Brien, Suman Rao, Katsuyuki Hotta, Melanie A Leiby, Gregory M Lbiniecki, Yue Shentu, Reshma Rangwala, Julie R Brahmer

    New England Journal of Medicine, 375(19):1823-1833, 2016.

  3. Pembrolizumab as First-line Therapy for Patients with PD-L1-positive Advanced Non-small Cell Lung Cancer: a Phase 1 Trial

    R. Hui, E.B. Garon, J.W. Goldman, N.B. Leighl, M.D. Hellmann, A. Patnaik, L. Gandhi, J.P. Eder, M.-J. Ahn, L. Horn, E. Felip, E. Carcereny, R. Rangwala, G.M. Lubiniecki, J. Zhang, K. Emancipator, C. Roach, N.A. Rizvi

    Annals of Oncology, 28(4): 874-881, 2017.

  4. Durvalumab after Chemoradiotherapy for Stage III Non-small-cell Lung Cancer (Times cited: ~3,189)

    S.J. Antonia, A. Villegas, D. Daniel, D. Vicente, S. Murakami, R. Hui, T. Yokoi, A. Chiappori, K.H. Lee, M. de Wit, B.C. Cho, M. Bourhaba, X. Quantin, T. Tokito, T. Mekhail, D. Planchard, Y.-C. Kim, C.S. Karapetis, S. Hiret, G. Ostoros, K. Kubota, J.E. Gray, L. Paz-Ares, J. de Castro Carpeno, C. Wadsworth, G. Melillo, H. Jiang, Y. Huang, P.A. Dennis, and M. Ozguroglu, for the PACIFIC Investigators.

    New England Journal of Medicine, 377(20): 1919-1929, 2017.

  5. Pembrolizumab plus Chemotherapy in Metastatic Non-small Cell Lung Cancer (Times cited: ~4,398)

    L. Gandhi, D. Rodriguez-Abreu, S. Gadgeel, E. Esteban, E. Felip, F. De Angelis, M. Domine, P. Clingan, M.J. Hochmair, S.F. Powell, S.Y. –S. Cheng, H.G. Bischoff, N. Peled, F. Grossi, R.R. Jennens, M. Reck, R. Hui, E.B. Garon, M. Boyer, B. Rubio-Viqueira, S Novello, T. Kurata, J.E. Gray, J. Vida, Z. Wei, J. Yang, H. Raftopoulos, M.C. Pietanza, M.C. Garassino for the KEYNOTE-189 Investigators.

    New England Journal of Medicine, 378 (22): 2078-2092, 2018.

  6. Overall Survival with Durvalumab after Chemoradiotherapy for Stage III NSCLC (Times cited: ~2,102)

    S.J. Antonia, A. Villegas, D. Daniel, D. Vicente, S. Murakami, R. Hui, T. Kurata, A. Chiappori, K.H. Lee, M. de Wit, B.C. Cho, M. Bourhaba, X. Quantin, T. Tokito, T. Mekhail, D. Planchard, Y.-C. Kim, C.S. Karapetis, S. Hiret, G. Ostoros, K. Kubota, J.E. Gray, L. Paz-Ares, J. de Castro Carpeno, C. Faivre-Finn, M. Reck, J. Vansteenkiste, D. Spigel, C. Wadsworth, G. Melillo, M. Taboada, P.A. Dennis, and M. Ozguroglu, for the PACIFIC Investigators.

    New England Journal of Medicine, 379 (24): 2342-2350, 2018.

  7. Patient-Reported Outcomes with Durvalumab After Chemoradiotherapy in Stage III, Unresectable Non-Small Cell Lung Cancer (PACIFIC): A Randomised, Controlled, Phase 3 Study

    Rina Hui, Mustafa Özgüroğlu, Augusto Villegas, Davey Daniel, David Vicente, Shuji Murakami, Takashi Yokoi, Alberto Chiappori, Ki Hyeong Lee, Maike de Wit, Byoung Chul Cho, Jhanelle E. Gray, Anna Rydén, Louis Viviers, Lynne Poole, Yiduo Zhang, Phillip A. Dennis, and Scott J. Antonia

    Lancet Oncology, 20:1670-1680, 2019.

  8. Lucitanib for the Treatment of HR+/ HER2-  Metastatic Breast Cancer: Results from the Multicohort Phase II FINESSE Study

    Rina Hui*, Alex Pearson*, Javier Cortes, Christine Campbell, Camille Poirot, Hatem A. Azim Jr, Debora Fumagalli, Matteo Lambertini, Fergus Daly, Amal Arahmani, J.M. Perez-Garcia, Philippe Aftimos, Philippe Bedard, Laura Xuereb, Elsemieke D. Scheepers, Malou Vicente, Theodora Goulioti, Sibylle Loibl, Sherene Loi, Marie-Jeanne Pierrat, Nicholas Turner, Fabrice Andre, Giuseppe Curigliano. (*Equal first authors)

    Clinical Cancer Research, 26: 354-363, 2020.

  9. Pembrolizumab for Early Triple-Negative Breast Cancer (Times cited: ~1,181)

    P. Schmid, J. Cortes, L. Pusztai, H. McArthur, S. Kummel, J. Bergh, C. Denkert, Y.H. Park, R. Hui, N. Harbeck, M. Takahashi, T. Foukakis, P.A. Fasching, F. Cardoso, M. Untch, L. Jia, V. Karantza, J. Zhao, G. Aktan, R. Dent and J. O’Shaughnessy, for the KEYNOTE-522 Investigators

    New England Journal of Medicine, 382: 810-821, 2020

  10. Event-free Survival with Pembrolizumab in Early Triple-Negative Breast Cancer

    P Schmid, J Cortes, R Dent, L Pusztai, H McArthur, S Kummel, J Bergh, C Denkert, Y H Park, R Hui, N Harbeck, M Takahashi, M Untch, PA Fasching, F Cardoso, J Andersen, D Patt, M Danso, M Ferreira, M A Mouret-Reynier, S A Im, J H Ahn, M Gion, S Baron-Hay, J F Boileau, Y Ding, K Tryfonidis, G Aktan, V Karantza, J O’Shaughnessy

    New England Journal of Medicine, 386: 556-567, 2022

 

h-index: 60; Citations: 36122

Cancer Research in HKUMed

Email: cancermed@hku.hk